Sep 11, 2023 / 11:00AM GMT
Arthur He - H.C. Wainwright & Co., LLC - Analyst
Greetings everyone and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Arthur He, a senior biotech analyst with the firm. It's my great pleasure to have Dr. Jay Short, the Chairman, CEO, and Co-Founder of BioAtla joining us for a fireside chat.
BioAtla is a clinical-stage biopharmaceutical company, developing novel therapies for solid tumors based on its proprietary conditionally active biologics platform. The company currently has four drugs in clinic and multiple preclinical candidates across different modalities. To discuss the company's CAB technology and its development strategy in 2023 and beyond, I welcome Jay, to this fireside chat.
Good day, Jay.
Jay Short - BioAtla, Inc. - Chairman, CEO & Co-Founder
Pleasure to be here. Thank you, Arthur.
Arthur He - H.C. Wainwright & Co., LLC - Analyst
I'm so glad to see you accepting our invitation to talk to our audience today. So, first place, to
Bioatla Inc at HC Wainwright Investment Conference - New York(Pre Recorded) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot